Eli Lilly Covid Antibody Drug Gets Emergency FDA Clearance
By News
Published 3 years ago on
November 9, 2020
Share
[aggregation-styles]
Bloomberg Subscription
Bloomberg Subscription
Eli Lilly & Co.’s antibody therapy was granted an emergency-use authorization by U.S. drug regulators for treating Covid-19, widening access to a treatment that early data suggests is effective in keeping people infected with the coronavirus out of the hospital.
The Food and Drug Administration authorized the treatment, called bamlanivimab, for use against mild-to-moderate Covid-19 in adult and pediatric patients, the agency said on its website.
Shares of Eli Lilly gained 4.5% in late trading on Monday. Through the close, the stock had advanced 8.3% so far this year.
By Riley Griffin | 9 Nov 2020
RELATED TOPICS:
What Did State Supreme Court Decide on Defamation Suit Against Assemblymember Soria?
Politics /
58 mins ago
Pennsylvania Nurse Who Gave Patients Lethal or Possibly Lethal Insulin Doses Gets Life in Prison
Crime /
2 hours ago
US Employers Scaled Back Hiring in April. How That Could Let the Fed Cut Interest Rates
Economy /
3 hours ago
Bulldog Football Outlook: More Explosive Offense, a Potential Game-Wrecker on Defense
Sports /
3 hours ago
Meet Goldie Hawn: The Adorable Yorkie with a Heart of Gold
Animals /
7 hours ago
Latest
Videos
Politics /
37 mins ago
Liar, Liar: Potential Trump VP Pick Noem’s Claims Are on Fire
Politics /
58 mins ago
What Did State Supreme Court Decide on Defamation Suit Against Assemblymember Soria?
Crime /
2 hours ago
Pennsylvania Nurse Who Gave Patients Lethal or Possibly Lethal Insulin Doses Gets Life in Prison
Economy /
3 hours ago